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The human endogenous retrovirus K (HERV-K) env gene encodes envelope protein
comprising surface (SU) and transmembrane (TM) domains. Having shown the
exclusive expression of SU in human breast cancer and the stimulation of SU-specific
immune responses in patients with breast cancer, our research here confirmed and
extended the data by investigating the expression of HERV-K TM envelope domain and
the induction of specific immune responses against TM in breast cancer patients. We
found HERV-K TM mRNA and protein expression only in human breast cancer cells but
not in normal controls. The specific immune responses against TM domain were induced
in mice determined by enzyme-linked immunosorbent assay (ELISA) and IFN-γ
enzyme-linked immunosorbent spot (ELISPOT) assay. Furthermore, ELISA detected
higher titers of anti-HERV-K TM Env IgG antibodies in sera of breast cancer patients. In
addition, the magnitude of the anti-HERV TM B cell response was correlated with the
disease stage. Peripheral blood mononuclear cells (PBMCs) before and after in vitro
stimulation (IVS) with HERV-K TM from patients with breast cancer as well as healthy
controls were tested for T cell responses against HERV-K TM domain by ELISPOT
assay. Breast cancer patients (n=21) had stronger HERV-K TM-specific cellular
responses than healthy controls (n=12) (P < 0.05). These findings suggest, for the first
time, that HERV-K TM expression was enhanced in human breast cancer cells and was
iv

able to induce specific B cell and T cell immune responses in breast cancer patients. This
study provides support for HERV-K TM as a promising source of antigen for anti-tumor
immunotherapy, prevention, diagnosis, and prognosis.
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Chapter 1 Introduction

Since a virus, later named as Rous sarcoma virus (RSV), was defined as the
transforming agent to propagate tumors in chickens by Peyton Rous in 1911, more
evidence has accumulated demonstrating the association between viruses and cancers.
Approximately 15-20% of human cancers can be linked to viral infection worldwide (1).
At least six viruses have been known to contribute to human malignancy. Epstein-Barr
virus (EBV), for example, the first discovered human cancer virus in 1965, is considered
as the etiologic agent of Burkitt’s lymphoma, nasopharyngeal carcinoma, and Hodgkin’s
lymphoma. Other notable associations are between Hepatitis B virus (HBV) and
hepatitis C virus (HCV) with hepatocellular carcinoma, high risk strains of human
papillomavirus (HPV) with cervical cancer, human T-cell lymphotropic virus type 1
(HTLV-1) with adult T-cell leukemia/lymphoma, and Kaposi’s sarcoma-associated
herpesvirus (KSHV) with Kaposi’s sarcoma (2).
Retroviruses are exceptionally important cancer-causing agents in animals and were
initially named as ‘RNA tumor viruses’. The original identification of oncogenic animal
retroviruses in chicken and mice stimulated intense interest to search for retroviruses in
humans. HTLV-1 was the first human exogenous retrovirus identified to be the
etiological agent of adult T-cell leukemia and lymphoma in 1980. As there is an analogy
of human exogenous retrovirus in the human genome to these viruses, human
endogenous retroviruses (HERVs) have recently been proposed to play a role in cancers,
including human breast cancer. In this section, we will focus on the general features of
HERVs and the association with human breast cancer.
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1.1 Human endogenous retrovirus (HERV)
1.1.1

Structure of HERV

HERVs are considered as the remnants of ancient exogenous retrovirus infection in
the host genome. HERVs are enveloped RNA viruses, characterized by two
characteristics of their replication: the ability to convert genetic information from viral
RNA into complementary DNA (cDNA) and the integration of the newly synthesized
DNA copy of viral RNA into the host genome. The process of the conversion of viral
RNA into cDNA is called reverse transcription, using the viral-encoding enzyme reverse
transcriptase. The latter feature provides a means for retroviruses to persist in the host
genome forming the endogenous retroviruses. The majority of the integrated provirus
becomes inactive given the accumulated random mutations during amplification in the
infected progeny host cells.
HERVs are typically 80 to 100 nm in diameter. The RNA genome, approximately 810 kb in size, is a dimer consisting of two identical linear (+) sense copies and is
associated with the nucleocapsid forming a ribonucleoprotein complex (Figure 1). The
viral genome are flanked by two copies of the long terminal repeat (LTR), which contain
important cis elements such as the promoter, enhancer, primer binding site, and polyA
sequences. The LTRs are important in initiating reverse transcription. Open reading
frames (ORFs) are located between the two LTRs and consist of four main genes coding
for the basic translated regions: gag, pro, pol, and env.
The gag gene codes for gag proteins composed of nucleocapsid, capsid, and matrix.
The pro gene codes for protease which is able to degrade viral precursor polyproteins to
make mature gag and pol proteins. The pol gene codes for reverse transcriptase and
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integrase which are essential for the reverse transcription process and the integration of
the proviral DNA into the host genome. The env gene codes for env proteins which are
composed of surface (SU) protein and transmembrane (TM) protein. SU protein is
responsible for the viral binding to the host cell receptor and TM protein is capable of
holding SU domain in the envelope and plays a role in the membrane fusion. The
ribonucleoprotein complex and the enzymes encoded by retroviruses are surrounded by
capsid protein and then matrix protein. The viral outer layer is made up of envelope
mediating viral entry (Figure 2).
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Figure 1 Schematic representation of the proviral form of a retrovirus and its env gene
products. Reprinted from reference (3) with permission from American Society for
Microbiology.
(a) Genomic proviral structure and delineation of the SU and TM subunits encoded by
the env gene. (b) schematic structure of a retroviral envelope protein products. CC,
disulfide bond; ISD, immunosuppressive domain.
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Figure 2 Schematic structure of a retroviral particle. Reprinted from reference (4) with
permission from BioMed Central.
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1.1.2

Classification of HERV

Almost half of the human genome is derived from transposable elements (TEs)
including DNA-transposons (2.8%), non-LTR retroelements (33.9%), and LTR
retroelements (8.3%) (5). HERVs belong to the LTR retroelements which are divided
into groups by using different classification systems.
The most common way to classify HERVs is based on sequence of the primer
binding sites (PBSs) in LTRs. PBS is the region which is hybridized with a tRNA used
to initiate reverse transcription. The HERVs can be named by adding the single letter
amino acid code for tRNA specificity. For example, HERV-K would use a lysine tRNA
as its primer. But this method may contain some limitations when the same tRNAs are
used by distantly related HERV groups or when no tRNA information is available due to
mutations.
HERVs are also classified into three classes based on the phylogenetic analysis,
Class I, II, and III, based on sequence similarity to the exogenous retroviruses (Figure 3).
Exogenous retroviruses, belonging to the virus family Retroviridae, contain seven
genera: α retrovirus, β retrovirus, γ retrovirus, δ retrovirus, ε retrovirus, spumaretrovirus,
and lentivirus.
Class I HERVs are close to exogenous γ retroviruses such as murine leukemia virus
(MLV) and include 6 groups such as HERV-W, HERV-FRD, and HERV-H. HERV-W
and HERV-FRD proviruses have maintained expression and fusogenic capacity of the
envelope protein in trophoblast cells in the placenta, named syncytin-1 and syncytin-2,
respectively. The fusion mediated by these envelope proteins are thought to create a
layer of fused cells in the placenta, called syncytiotrophoblasts, which is important for
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placentogenesis and pregnancy. Class II HERVs include 10 groups which are close to β
retroviruses such as mouse mammary tumor virus (MMTV) and are known as HERV-K
when the lysine tRNA binding site sequence is used. Class III HERVs are distantly
related to spumaretroviruses and include a few groups like HERV-L and HERV-S (5).
Most HERVs appear to be ancient and are found in both Old and New World
monkeys, suggesting that the first integration occurred more than 35 million years ago
before the divergence of New World and Old World monkeys. HERV-K is the youngest
HERV and is the one most likely to be active. The age of an endogenous retrovirus can
be roughly estimated by comparing its two LTRs. At time of integration, both of the
LTRs should be identical. But over time, the accumulating mutations during the host
DNA replication process would generate one difference between two LTRs every
approximately 200,000 to 450,000 years. Studies show that some HERV-K members
have less than five differences between the two LTRs, suggesting that the integration
occurred only less than 1 million years ago.
The erratic way for the HERV classification and naming may cause some problems.
It may lead to, for example, different name designations for the same sequence. HERVK10, HTDV, and HERV-K, once named differently by various research groups, are
finally confirmed as the same HERV subfamilies. Recently, some new revised
classification systems are being developed based on a combination of similarity,
structure, function, and previous naming which are thought to be able to overcome the
classification problems (6, 7).

7

Figure 3 General tree of retroviruses based on the Pol proteins of exogenous and
endogenous retroviral sequences. Reprinted with reference (8) with permission from
BioMed Central.
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1.1.3

Physiological effects of HERV

Considering the retention of HERVs for over millions of years in the human
population during evolution, HERVs may provide beneficial functions for their hosts.
First, HERVs, as well as other TEs, may play a role in the shaping and plasticity of
the human genome. For instance, it has been found that HERV LTRs constitute
regulatory elements which provide promoter, enhancer, or polyadenylation signals for
nearby host DNA genes. HERV LTRs often contain the p53 regulatory binding sites and
may be involved in anti-tumor activity through the p53 pathway (9). Telomerase,
considered to stabilize the chromosomes, is shown to be derived from RTs.
Second, HERV-W envelope proteins can protect host cells from infections by closely
related exogenous retroviruses via receptor interference (10).
Third, some HERVs are associated with placenta formation. HERV-W and HERVFRD env genes, encoding the protein syncytin, namely syncytin-1 and syncytin-2,
respectively, are highly expressed in the placenta. They are thought to be function as
fusogenic activities by mediating the fusion of the cytotrophoblast into the
syncytiotrophoblast. Besides the function in placenta morphogenesis, the expression of
syncytin-2 may also contribute to prevention of allogeneic rejection of the fetus at the
fetal syncytiotrophoblast boundary by immunosuppressive activity; this is not the case
for syncytin-1 (11).
1.1.4

HERV and human diseases

Considering the pathologic properties of human exogenous retroviruses, it is easily
understood that the primary effects of HERVs for the host is not beneficial but
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detrimental. The scientific literature has shown that HERVs are tentatively involved in
several types of human diseases including autoimmune diseases and cancers (12).
Based on the observation of retroviral antibodies in the plasma of patients and the
presence of amplified products homologous to HERVs, HERVs have been considered to
be associated with several types of human autoimmune diseases such as lupus
erythematosus, insulin-dependent diabetes mellitus, multiple sclerosis, and rheumatoid
arthritis. Several mechanisms have been documented to be involved in the dysregulation
of the host immune system by HERVs (13). The insertion of the proviral HERVs into
the certain host genes associated with immune regulation may contribute to the diseases
(14). Moreover, HERVs may express some ‘foreign’ proteins which would trigger
immune responses to produce antibodies causing cross-reaction against our own proteins
(15). HERVs can also encode some superantigen proteins which are able to trigger
strong immune responses by expansion of autoreactive T lymphocytes (16). It is also
shown that the envelope proteins encoded by class I HERVs are capable of activating the
innate immune cells to cause the production of several cytokines, which, in turn can act
on T lymphocytes (17). In addition, the HERV SU envelope proteins can activate
dendritic cells and further promote Th1-like immune responses (18).
HERVs are transcriptionally and translationally active in many different types of
human cancers such as germ cell tumors, melanoma, and breast cancer (Table 2). Even
though cumulative evidence has shown that HERVs may be involved in the process of
carcinogenesis, the contributions of HERVs to human cancers appear more complex.
Several potential mechanisms of HERV in human cancer development have been
discussed (19).
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First, HERVs are assumed be able to play a role in human cancers by insertional
mutagenesis indicating retroviral movement in the genome. But it must be emphasized
that there is no replication-competent HERVs identified in present-day human
individuals.
Second, HERVs may contribute to human cancers by the action of two accessory
oncoproteins encoded by HERV-K. They are termed Rec and NP9. Rec is functionally
related to the regulatory proteins HTLV Rex and HIV Rev, responsible for the nuclear
export of retroviral mRNA into the cytoplasm. It has been found that both Np9 and Rec
are involved in cellular transformation under certain conditions, and Rec is able to cause
carcinoma in transgenic mice (20). They can directly bind the promyelocytic leukaemia
zinc finger (PLZF) which is known as a tumor suppressor of c-myc. The inhibition of the
transcriptional inhibiting activity of PLZF by Rec or NP9 results in the elevated
expression of c-myc and of c-myc responsive genes such as p53, PCNA and IkBa.
Moreover, NP9, in contrast to Rec, is involved in the Numb/Notch pathway by binding
to and interfering with the ligand of Numb protein X (LNX), a RING-Type E3 ubiquitin
ligase. Notch signaling has been suggested to be involved primarily in breast cancers,
leukemias, and germ cell cancers (21).
Third, endogenous retroviral envelope proteins may mediate immunosuppressive
activity resulting in tumor escape considering the evidence from research in animals (22).
Further studies are needed to clarify whether the HERV envelop proteins are
immunosuppressive and expressed in human cancer. Moreover, it has not been
demonstrated up to now whether the increased expression of some elements of HERVs
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precedes the human cancers or whether they are the results of altered gene regulation in
tumor cells.
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Table 1 HERV-encoded proteins previously detected in human tumors and tumor
cell lines.

Reprinted from reference (19) with permission from Springer.
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1.2 Human breast cancer
1.2.1

General features of breast cancer

Breast cancer arises from the epithelial cells of the breast and is the most common
cancer among women. It is estimated that around one in ten women will develop breast
cancer in their lifetime worldwide. In 2011, about 288,130 new breast cancer cases are
expected to occur among US women (American Cancer Society. Cancer Facts & Figures
2011 [online]). Whereas the mortality from breast cancer has largely decreased since
1990 as a result of earlier diagnosis and improved treatment, breast cancer is the second
cause of cancer death in women, exceeded only by lung cancer. Around 39,520 women
are expected to die from breast cancer in 2011, accounting for 15% of all cancer death in
US women.
A wide variety of risk factors influencing an individual's likelihood of developing
breast cancer has been established. Two most important risk factors are being female and
increasing age. Other potential risk factors include being overweight or obese, hormone
therapy, low physical activity, dense breast tissue, previous chest radiation, a long
menstrual history, oral contraceptive usage, never having children or late age at first
pregnancy, and a previous personal history of breast cancer. Moreover, women with
positive family histories of breast cancer have a 2- to 3-fold increased risk of developing
malignancy. An inherited mutation in the BRCA1 or BRCA2 tumor-suppressor genes is
the strongest known indicator of hereditary breast cancer risk. Genetic mutations in
either of these two genes are responsible for a 40-80% chance of developing inherited
breast cancer (23).
1.2.2

Viral etiology of breast cancer
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Human breast cancer is a highly heterogeneous malignancy with different biological,
histopathological, genetic, epidemiological, and clinical features. This heterogeneous
characteristic could well suggest that multiple causal agents play significant roles in the
initiation and development of human breast cancer (24). An immense current research,
although not conclusive, shows that three viruses are potentially involved in causing
breast cancer: human papillomavirus (HPV), MMTV-like virus, and EBV (25). MMTV,
belonging to β-retroviruses, has been proved to be the cause of mammary cancer in mice.
So, similar viruses have long been investigated as a potential cause of human breast
cancer. Recently, MMTV-like genetic material and viral particles have been identified in
human breast cancer (26). Moreover, more evidence shows that HERV-K,
approximately 57% homologous to MMTV gene sequence, is expressed in human breast
cancer. In addition, a few more viruses have recently been shown to be associated with
human breast cancer. These include bovine leukemia virus (BLV) and
cytomegaloviruses (CMV) (27).
1.3 Involvement of HERV-K in human breast cancer
As mentioned above, almost all the HERVs are defective due to the accumulating
mutations, premature stop codons, truncations, etc. But, HERV-K is the only one
possessing the replication activity capable of encoding all viral proteins such as gag, pro,
pol, and env proteins. HERV-K is comprised of two types based on the presence or
absence of a 292-bp at the pol-env boundary. Type I HERV-K displays the absence of a
292-bp at the pol-env boundary, whereas type II is presence of this region. Type II, the
HERV-K prototype, expresses the accessory protein Rec, which functions in
transporting viral RNA from nucleus into cytoplasm. Type I, instead, encodes the
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synthesis of another accessory protein NP9, which is considered to be associated with
tumorigenesis (28).
HERV-K SU env mRNA and proteins have been found to be overexpressed in many
breast cancer cell lines and breast tumor tissues but not in normal breast tissues (29, 30).
Beyond the expression of retroviral gene fragments, researchers also focus on the
discovery of HERV-K viruses and hope to find a replication competent virus. An earlier
study shows that HERV-K viral-like particles were identified from the human breast
cancer cell line T47D (31). A recent study suggests that HERV-K viral-like particles
could be found in the sera from lymphoma patients under an electron microscope (EM)
(32). Moreover, reanimated HERV-K viral-like particles constructed by correcting the
mutations are capable of replicating (33). These experiments demonstrated the potential
capability of HERV-K to replicate in the past, but they do not directly address whether
HERV-K can still produce infectious viruses in modern humans. In addition, HERV-K
components are documented to be immunogenic. Antibodies against HERV-K SU
envelop protein have been detected by western blot and ELISA in a proportion of breast
cancer patients (30). Cytolytic lymphocytes (CTLs) have been found to be able to kill
the HERV-K SU envelop-expressing breast cancer cells (30).
1.4 Hypothesis and specific aims of this study
As mentioned above, the findings that HERV-K SU envelope protein is specifically
overexpressed in human breast cancer and immune responses against HERV-K SU
envelope protein are induced in breast cancer patients but not in normal donors have
indicated the possibility that HERV-K may represent an ideal target for diagnosis,
prevention, and treatment of breast cancer. In this regard, we further focused on the other
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domain of HERV-K env, namely the HERV-K TM, to analyze the reactivity in breast
cancer. Some evidence has shown that HERV TM protein was especially strongly
expressed in human melanoma biopies (34) and in some human cancer cell lines
including colon and prostate carcinoma cell lines (35). Furthermore, anti-TM antibody in
sera was detected in 22% of melanoma patients but not in healthy individuals (34).
Based on these previous studies we hypothesized that HERV-K TM envelope
protein was a potentially valuable source of tumor-associated antigen which was
exclusively expressed and elicits specific immune responses in human breast cancer,
and could thereby be used for breast cancer immunotherapy or diagnosis. The
hypothesis was tested by completing the following two specific aims.
Specific aim 1 To determine the expression of HERV-K TM envelope mRNA and
protein in human breast cancer.
Specific aim 2 To determine TM-specific humoral and cellular immunological
responses in breast cancer patients.

17

Chapter 2 Materials and Methods

2.1 Cell lines and clinical samples
A number of human breast cancer cell lines including SKBR3, T47D, MDA-MB231, and MDA-MB-453 were obtained from American Type Culture Collection
(Rockville, MD). The breast cancer cell line MCF-7 was a kind gift from Dr. Melinda
Hollingshead (Developmental Therapeutics Program, DCTD, NCI). The normal human
breast epithelial cell line MCF10A was a kind gift from Dr. Robert Pauley (Karmanos
Cancer Institute). MCF10A was cultured in Dulbecco's Modified Eagle Medium:
Nutrient Mixture F-12 (DMEM/F12) medium supplemented with 5% horse serum, 10
µg/mL insulin, 20 ng/mL EGF, and 1× pen/strep. SKBR3 was cultured in DMEM
medium supplemented with 10% fetal bovine serum (FBS), 2 mM L-glutamine and 1×
pen/strep. The other cell lines were cultured in complete RPMI 1640 medium (i.e.,
PRMI 1640 supplemented with 10% FBS, 2 mM L-glutamine, and 1× pen/strep). T47D
cells were treated with 10 µg/mL insulin.
With the informed consent, blood samples, breast tissue biopsies, and healthy female
controls were obtained from human subjects at the M. D. Anderson Cancer Center
according to the approved Institutional Review Board (IRB) protocols. Sera from breast
cancer patients at different stages as well as healthy controls were a kind gift from
collaborators at NIH.
2.2 RNA isolation and reverse transcription-polymerase chain reaction (RT-PCR)
Total RNA was isolated from the cultured cell lines in Tri-reagent (Sigma, St. Louis,
MO) according to the manufacturer's instruction. The resulting RNA was treated with
RNase-free DNase I (Ambion, Austin, TX) at 37°C for 30 min to prevent the
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contamination of genomic DNA, followed by heating at 75°C for 5 min to inactivate
residual DNase.
RT-PCR to amplify TM gene was performed as described previously (29). Briefly, a
first strand cDNA was synthesized from the RNA template using Ready-To-Go™ YouPrime First-Strand Beads (GE healthcare). 10 µg RNA was added into 32 µL
Diethylpyrocarbonate (DEPC)-treated H2O and heated at 65°C for 10 min. 1 µL random
primers (Promega) was added to the quenched RNA solution and then incubated with the
beads at 37°C for 1 hr. 3.3 µL cDNA, corresponding to 1 µg of input RNA, was
amplified in a final volume of 50 µL reaction system containing 5 µL of 10× PCR buffer
(Fisher), 0.25 µL of Taq DNA polymerase (1.25 units; Fisher), and the TM outer primer
pair at 1 mM each (sense primer:5’ AGT CGG TAA ACT TTG TTA ATG 3’ ; antisense
primer: 5’ TCT CCT ATG TCT ACT TCT TT 3’). β-actin was synthesized in parallel
with human β-actin primers to show the same amount of cell loaded. After the initial
denaturation step at 94°C for 3 min, 30 cycles of amplification were performed as
follows: denaturation at 94°C for 1 min, annealing at 55°C for 1 min, and extension at
72°C for 1 min. The amplified genes were finally extended at 72°C for 10 min. The RTPCR product was subjected to electrophoresis on a 1% agarose gel by ethidium bromide
staining to check the insert size.
2.3 Construction and characterization of HERV-K TM expression vector
The DNA fragment encoding TM was amplified by RT-PCR from a human
melanoma patient sample using the same conditions as described above and then
amplified by nested PCR with a TM inner primer pair incorporating the restriction
enzyme sites BamHI and HindIII (i.e., sense primer 5’ CGG GAT CCA TTG GCA AAA
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GAA TTC TG 3’; anti-sense primer 5’ CCC GGG AAG CTT CTA CAC AGA CAC
AGT AAC 3’). The nested PCR product was purified using a Gel Extraction Kit (Qiagen
Inc., Chatsworth, CA) and further cloned into the pCR2.1 vector (Invitrogen, Carlsbad,
CA). The recombinant plasmid was amplified by PCR and subjected to gel
electrophoresis. The bacterial clones containing the insert fragment with expected size
were combined and the plasmids were purified by mini-prep using a QIAprep Spin
Miniprep Kit (Qiagen Inc., Chatsworth, CA). The TM fragment was digested from the
recombinant plasmid pCR2.1-TM by double restriction digestion with BamHI and
HindIII, purified from agarose gel, and then subcloned in frame into the same restriction
sites downstream of the histidine hexamer (6-His) in prokaryotic expression vector
pQE30 followed by transformation in E. Coli BL21 (Qiagen Inc., Chatsworth, CA). The
transformed bacteria were cultured in LB broth containing 100 µg/mL ampicillin and 25
µg/mL kanamycin. The recombinant plasmids were screened by PCR and again
subjected to double restriction digestion. The candidate recombinant clones containing
the insert with the predicted size were induced on a small-scale using 0.1 mM isopropylβ-D-thiogalactoside (IPTG) at 18°C overnight. The ability of the candidate clones to
produce TM fusion protein was assessed by Coomassie blue staining and Western blot.
One recombinant pQE30-TM clone expressing the expected fragment was chosen to be
further confirmed by sequencing using the recommended sequencing primers (Qiagen
Inc., Chatsworth, CA). The clone with the complete TM sequence was retained for TM
protein purification as described below.
2.4 Expression and purification of recombinant fusion TM protein in E. coli
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To express the TM fusion protein, the recombinant pQE30-TM bacterial clone,
confirmed by western blot and sequencing, was grown in LB broth containing both
ampicillin (100 µg/mL) and kanamycin (25 µg/mL) at 37°C with vigorous shaking (i.e.,
250 rpm) until an OD600 of 0.8 was reached. The culture was induced overnight by
adding 1 mM IPTG at 18°C. The induced culture was spun down at 6,000 × g for 10 min
at 4°C and frozen at -20°C overnight.
The 6×His-tagged fusion protein was purified using Ni-NTA affinity
chromatography under the recommended conditions (Qiagen Inc., Chatsworth, CA).
Briefly, the frozen bacterial pellet was thawed on ice and resuspended in lysis buffer (50
mM NaH2PO4, 300 mM NaCl, 10 mM imidazole, pH 8.0) at 3 mL/g net weight.
Lysozyme was added to 1 mg/mL. After 30 min incubation on ice, the cell suspension
was sonicated with six 10 s bursts at 80-100 W with a 10 sec cooling period between
each burst and then spun down at 10,000 × g for 10 min at 4°C to pellet the cellular
debris. The Ni-NTA slurry, pre-equilibrated with the same lysis buffer, was added to the
cleared lysate and incubated overnight by gently shaking (100 rpm) at 4°C. The lysateNi-NTA mixture was added into a column pre-equilibrated with wash buffer (50 mM
NaH2PO4, 300 mM NaCl, 20 mM imidazole, pH 8.0). After washing the column twice
with the same wash buffer, the bound protein was eluted with elution buffer (50 mM
NaH2PO4, 300 mM NaCl, 250 mM imidazole, pH 8.0). The protein product was dialyzed
in cold phosphate buffered saline (PBS) overnight at 4°C. After sterilization, endotoxin
removal from the protein was performed using Detoxi-gel endotoxin removing gel
(Thermo Scientific, Rockford, IL) as described by the manufacturer. Purified fusion
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protein was analyzed by Coomassie blue staining and western blot. Protein concentration
was measured by Bradford assay using the Quick Start Bradford 1× Dye Reagent.
2.5 Coomassie blue staining and Western blot
The purified TM protein (typically 10 µg) for sodium dodecyl sulfatepolyacrylamide gel electrophoresis (SDS-PAGE) was preheated at 100°C for 5 min in a
6× Laemmli buffer. The sample was run on 12% SDS-PAGE gel at 120 V for about 2 hr
in a Laemmli sample buffer (1 g/L SDS, 3.03 g/L Tris base, and 14.4 g/L glycine). The
gel was fixed with de-stain buffer (40% v/v methanol and 10% v/v acetic acid) for 30
min and then stained with Coomassie blue stain, which contained 0.1% (w/v) Coomassie
blue R250, 40% methanol, and 10% acetic acid at room temperature for 1 hr with gentle
agitation.
For Western blot, the protein in the gel was transferred to a nitrocellulose membrane
(Bio-rad laboratories, Hercules, CA) at 100 mA for 2 hr in a transfer buffer (3.03 g/L
Tris base, 14.4 g/L glycine, and 20% v/v methanol). After washing in Tris buffered
saline (TBS, 17.53 g/L NaCl and 4.85 g/L Tris base, pH 7.5) for 5 min, the membrane
was blocked in blocking buffer containing 3% (w/v) non-fat dried milk in TBST (i.e.,
TBS containing 0.2% Tween 20) for 1 hr at room temperature with gentle shaking (100
rpm). After washing three times with TBST for 10 min, the membrane was then
incubated overnight with the primary anti-mouse RGS·His antibody (Qiagen Inc.,
Chatsworth, CA) at 1:1000 dilution in the same blocking buffer at 4°C. After washing
shown as above, the membrane was incubated with the secondary 1:5000 diluted antimouse IgG antibodies conjugated with horseradish peroxidase in the blocking buffer at
room temperature for 1 hr. The membrane was washed again, developed using
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Visualizer™ Spray & Glow™ detection reagent (Millipore, Billerica, MA) and exposed
to X-ray film.
2.6 Immunization, mouse polyclonal antibodies and spleen cells
Female HLA-A2 transgenic C57BL/6 mice (6-8 week old) were subcutaneously
immunized with 100 µL volume containing 100 µg purified recombinant HERV-K TM
fusion protein each mixed with the same volume of complete Freund’s adjuvant (CFA).
Three more boosters were given at the same dose in incomplete Freund’s adjuvant (IFA)
at weeks 4, 5, and 6. Another group of mice, considered as mock mice, were inoculated
with a control consisting of 100 µL PBS mixed with the same volume of adjuvant.
Ten days after the last booster, the mice were sacrificed using CO2 and bled from the
heart. To collect the serum, the blood was left to coagulate at room temperature for more
than 30 min and spun down at maximum speed for 5min at 4C. The harvested serum was
stored at -80°C prior to analysis by enzyme-linked immunosorbent assay (ELISA) and
immunofluorescence staining (IFS) assay.
The spleen cells from the immunized mice were also collected. Briefly, the spleen
was removed aseptically and homogenized with homogenizer. The viable spleen cells
were isolated by Histopaque 1083 density gradient centrifugation (Sigma, St. Louis,
MO) following the manufacturer’s instructions. Red blood cells were completely
removed from the spleen cells using red blood cell lysis buffer (8.3 g/L NH4Cl, 1 g/L
KHCO3, and 0.09 g/L EDTA). After washing with PBS, the spleen cells were frozen in
liquid nitrogen and analyzed by enzyme-linked immunosorbent spot (ELISPOT) assay.
2.7 Primary cell isolation from human breast cancer clinical samples
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Breast tumor or nonmalignant tissue was thoroughly washed 3 times with PBS and
then minced into small pieces in a Petri dish using a sterile scalpel (Feather #10) in 5mL
complete NOE culture medium (i.e., DMEM/M199 supplemented with 10% FBS and 1×
Pen/Strep). Contents of the Petri dish were transferred into a 50mL conical tube. 30 mL
of the complete culture medium was added to the sample and then mixed and spun down
at 2,000 rpm for 5 min. The supernatant was decanted and the pellet was washed once
using PBS. The pellet was digested with AccuMax (Sigma, St. Louis, MO) at 37°C for 1
hr. After spinning down at 2,000 rpm for 5 min, the pellet was resuspended in 40 mL
complete culture medium. The sample was homogenized by inserting a Stomacher 80
bag containing the sample into a Stomacher 80 (Seward, West Sussex, UK) and running
the Stomacher 3 times for 2 min at high speed. The sample was transferred to a new 50
mL conical tube and spun down again. After washing, the primary human breast tumor
cells were placed onto a 6-well plate in 12 mL of complete culture medium and
incubated in a 5% CO2 incubator at 37°C.
2.8 Peripheral blood mononuclear cell (PBMC) isolation from human blood
samples
PBMCs were isolated from the whole blood samples by density gradient
centrifugation using Histopaque-1077 (Sigma, St. Louis, MO). Briefly, 10 mL of blood
from a heparinized tube was transferred to a 50 mL Falcon tube and spun down at 2,000
rpm for 5 min at room temperature. The upper layer (i.e., plasma) was collected without
disturbing the lower layers and stored at -80°C for future analysis. 30 mL of PBS was
added to the remaining blood and mixed well by gentle pipetting. The diluted blood
sample was then carefully and very slowly added to a 50 mL Falcon tube previously
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loaded with 10 mL Ficoll-1077 without breaking through the Ficoll layer. The tubes
were spun down at 1,500 rpm for 30min at room temperature using slow acceleration
and deceleration rates. PBMCs were recovered by collecting the all three layers (i.e.,
PBS, PMBCs, and Ficoll layers) without the bottom layer of erythrocytes and
granulocytes with a 10 mL pipette and placed to a new 50 mL tube. The cells were
washed by adding 30 mL PBS and spun down at 1,000 rpm for 10 min at room
temperature. The supernatant was discarded. 5mL of RBC Lysis Solution (8.3g NH4Cl,
1.0g KHCO3, and 1.8ml of 5% EDTA in 1L distilled H2O)was added to the cells and the
mixture was incubated for 5 min at room temperature. After washing three times with
PBS, the PBMCs were re-suspended in complete RPMI 1640 culture medium at
5×106/mL, seeded in a 6-well plate, and cultivated in a 37°C incubator overnight for
dendritic cell (DC) preparation as described below.
2.9 DC and in vitro stimulation (IVS) cell preparation
For generating DCs, non-adherent cells were removed from the overnight culture of
PMBCs with a pipette. The wells containing the adherent cells were gently washed with
2 mL/well of RPMI 1640 kept at 37°C to remove the remaining non-adherent cells. The
washing step was repeated once. 2 mL/well of fresh complete RPMI 1640 was added to
the plate and cells were incubated with 1,000 units/mL each of granulocyte macrophage
colony-stimulating factor (GM-CSF) and interleukin (IL)-4. Six days later, the immature
DCs were harvested from the plate with a pipet and pulsed with HERV-K SU or TM
protein using BioPORTER protein delivery reagent (Genlantis) according to the
manufacturer’s instructions. DCs were incubated with a protein/bioporter mixture for 4
hrs at 37°C. After washing, the pulsed DCs were cultured overnight in complete RPMI
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1640 medium containing 7.5 ng/mL tumor necrosis factor-α (TNF-α) to induce DC
maturation.
To prepare in vitro stimulation (IVS) cells, autologous PBMCs were added to
protein-pulsed DCs at a DC to PBMC ratio of 1:30. The cells were cultured in the
presence of 10 units/mL of rhIL-2 and the culture medium with rhIL-2 was exchanged
every 2-3 days. After 7 days, IVS cells were collected and ready for analysis.
2.10 Immunofluorescence staining (IFS) assay
Indirect IFS assay for the analysis of HERV-K TM Env protein expression was
performed by seeding cultured cells (e.g., MCF10A, MDA-MB-231, SKBR3, and
primary cell culture from human breast cancer tissue as well as uninvolved breast tissue)
on sterile glass cover slips in 6-well plates (50,000 cells per well) and incubation
overnight in a 37°C incubator. After washing once with PBS, the cells were fixed and
permeablized in 100 µL of Cytofix/Cytoperm solution (BD) per slip for 20 min at room
temperature. The cells were then washed twice with Perm/Wash buffer (BD) and
incubated with 100 µL blocking buffer (3% BSA in BD Perm/Wash buffer) per slip for
30 min at room temperature to block the nonspecific binding. After washing, the cells
were stained by sequential incubation with mouse antisera against TM diluted 1:100 in
blocking buffer for 1 hr at room temperature and anti-mouse IgG conjugated with Alexa
Fluor-488 diluted in 1:200 for 30 min at room temperature. Control staining was
performed with the corresponding sera from mice injected with PBS. After washing
again, the cellular nuclei were stained with 4',6-Diamidino-2-phenyindole (DAPI;
Invitrogen) according to the manufacturer's instructions. The cells were mounted with
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90% glycerol in water and examined under a laser-scanning confocal microscope
(LeicaSP5) with appropriate filters.
The protocol above was modified to characterize the epithelial phenotype of primary
cell culture from breast cancer patient samples. Anti-vimentin (1:100) and anti-pancytokeratin (1:100) polyclonal antibodies (Sigma) were used as the first antibodies.
2.11 Enzyme-linked immunosorbent assay (ELISA)
ELISA was used to detect anti-HERV TM IgG antibodies in sera from human
samples or mice as described previously (36). Briefly, the wells of a 96-well plate were
coated with 100 µL/well of 10 µg/mL purified HERV-K SU or TM fusion protein in
PBS and incubated overnight at 4°C. The coating solution was discarded and the plate
was washed six times with PBS. The coated wells were blocked by adding 100 µL/well
blocking buffer (3% BSA in PBS) for 2 hrs at room temperature. 100 µL/well diluted
sera were added and incubated overnight at 4°C. After washing, 100 µL/well speciesspecific anti-IgG antibody conjugated with HRP (1: 4,000 dilution, Sigma) was added
and incubated for 1 hr at room temperature. After washing again, 100 µL/well freshlymade ABTS substrate solution (200 µL ABTS and 10 µL 30% H2O2 in 10 mL citrate
buffer) was added and the absorbance was measured with a 1420 multilabel counter
(PerkinElmer, Shelton, CT) at 405 nm at different time points. The ELISA was
performed in triplicate for each dilution.
2.12 Enzyme-linked immunosorbent spot (ELISPOT) assay
Direct ELISPOT assay was performed on a 96-well ELISPOT plate (Millipore) to
quantify antigen dependent IFN-γ secreting mouse spleen cells. Briefly, the ELISPOT
plates were pre-wetted with PBS for 45 min at room temperature and coated with 100
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µL of 5 µg/mL anti-mouse IFN-γ antibody (Mabtech) per well by incubating the plate
overnight at 4°C. The plates were washed once with PBS and blocked with 100 µL of
10% fetus bovine serum (FBS) in PBS per well for 40 min at room temperature. After
washing with PBS, test spleen cells from immunized mice were added at 5×105 per well
and re-stimulated with 20 µg/mL HERV-K TM protein in a total volume of 100 µL
complete RPMI medium. The assay was performed in triplicate in all experiments. The
seeded cells were incubated in a 37°C incubator for 18-24 hrs. After incubation, the
plates were washed five times with PBS and incubated with 100 µL/well biotinylated
anti-mouse IFN-γ antibody (Mabtech) at 1 µg/mL in PBS containing 0.5% FBS at room
temperature for 2 hrs. After washing again with PBS, 100 µL of alkaline-phosphatase
streptavidin (1/1000 in PBS containing 0.5% FBS; Sigma) was added to each well and
incubated at room temperature for 1.5 hrs. The plates were washed again and developed
for less than 10 min at room temperature by adding 100 µL/well of NBT/BCIP substrate
(Sigma, St. Louis, MO) in distilled deionized water (ddH2O) prepared following the
manufacturer's instructions. The reaction was stopped by washing the plate three times
with tap water. Spots were counted with the aid of an ELISPOT reader (C.T.L., Shaker
Heights, OH). Only the number of TM-dependent IFN-γ secreting cells is reported in
each case. The spleen cells from the mice immunized with PBS were run in triplicate as
negative control to ensure that spot formation requires the immunization with the
antigen. Keyhole limpet hemocyanin (KLH) was also used as a negative control in this
assay. The results are expressed as the number of IFNγ secreting cells per 5×105 cells.
Anti-human IFN-γ ELISPOT assay was used for monitoring specific cellular
immune responses against HERV-K SU and TM proteins in breast cancer patient
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samples (30). The pre-wet ELISPOT plates were coated with 5 µg/mL of anti-human
IFN-γ antibody (Mabtech) and incubated overnight at 4°C. The plates were then blocked
with complete RPMI medium for 2 hrs at room temperature. PBMC, IVS TM or IVS SU
cells were plated at 50,000 cells per well with the autologous DCs pulsed by
corresponding proteins at 2,500 cells per well. The plates were incubated for 18-24 hrs at
37°C and developed and read as described above.
2.13 Statistical analysis
Analyses were done using GraphPad Prism version5. Statistical significance between
groups was determined by a Student’s t test. Difference among the populations with
cancer at various phases was determined by a ANOVA analysis. A difference was
regarded as significant if the p value was less than 0.05.
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Chapter 3 Results

3.1 Production and characterization of TM protein
To experimentally characterize the TM envelope domain of HERV-K, we first
developed the TM-expressing vector and generated the purified TM fusion protein. The
construction of protein expression vector containing the HERV-K TM protein DNA
sequence (pQE30-TM) was carried out according to the flowchart shown in Figure 4.
Total RNA was derived from melanoma cell culture from a melanoma patient. A 591 bp
DNA sequence coding for TM was amplified by RT-PCR and nested PCR, and then
ligated with TA cloning vector pCR2.1 to form the recombinant plasmid pCR2.1-TM.
The recombinant was identified by PCR and the fragment was analyzed by 1% agarose
gel electrophoresis. Nineteen of twenty screened clones showed PCR product with the
expected size.
To increase the possibility of obtaining translationable sequence without the
premature stop codon, all of the nineteen successfully cloned recombinants were
combined to prepare a small amount of plasmid mixture (Figure 5). After double
digestion, gel extraction, and ligation reaction, the sequence coding for HERV-K TM
was cloned from the mixed pCR2.1-TM into the prokaryotic expression vector pQE30 in
E. coli host strain BL21. Among the twenty-four recombinants screened, ten were
identified that contained the inserted sequence with the expected size by PCR and double
digestion (Figure 6A and 6B). Furthermore, Coomassie blue staining and Western blot
were carried out to confirm the ability of the recombinant vector to express the fusion
protein of interest. Results showed that seven clones were positive for protein production
(Figure 7). One clone (clone#23) was chosen for sequencing and sequence comparison
30

with several HERV-K TM sequences showed the cloned nucleic acid sequence most
closely resembled (99% homology) the TM of HERV-K 37 (accession number:
DQ112095; Figure 8). All the three positions in nucleic acid sequence from the clone 23,
which are different from KERV-K37, occurred in the third base of the triplet codon, so
there are no amino acid differences between them. The sequence is also highly
homologous to the TM gene of HERV-K113 (96%; accession number: AY037928) and
HERV-K115 (97%; accession number: AY037929), which are known full-length, intact
HERV-K elements and which are polymorphic in human genome.
After induction with IPTG, the recombinant clone #23 containing HERV-K TM was
expressed in E.coli BL21 to produce the 6-His TM fusion protein. The TM protein was
purified using Ni-NTA coupled to agarose chromatography beads and purity was
demonstrated by SDS-PAGE. A unique protein band with the predicted molecular mass
(about 25 kDa) was observed using Coomassie blue staining and Western blot (Figure 9).
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Figure 4 Flowchart of cloning and construction of the recombinant plasmid pQE30-TM
expressing TM fusion protein of HERV-K.
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Figure 5 Screening of recombinant plasmid pCR2.1-TM by PCR.
Using standard procedures for ligation, HERV-K TM fragment amplified from a
melanoma patient was cloned into pCR2.1 vector. The candidate recombinant clones
were screened by PCR using TM outer primers. This figure shows that a DNA fragment
with the expected size was amplified from the majority of the recombinant clones (clone
#1-13) except for clone #13.
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Figure 6 Screening and identification of pQE30-TM by PCR and double digestion
reaction.
(A) The TM gene cloned into the pCR2.1 vector was ligated with the prokaryotic
expression vector pQE30 using BamHI and HindIII sites to construct the recombinant
plasmid pQE30-TM. After transformation, twenty-four clones of the candidate
recombinant vector were screened by regular PCR with the TM inner primer pair under
the conditions shown in the text. The figure shows ten of these clones (clone #7, #12,
#13, #14, #15, #17, #18, #20, #21, and #23) that contained an insert fragment with the
expected size.
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Figure 6 Screening and identification of pQE30-TM by PCR and double digestion
reaction.
(B) The ten PCR-positive recombinant vectors were further characterized by double
digestion reaction with BamHI and HindIII. This figure shows that all clones contained
the insert fragment with the expected size. The empty vector pQE30 was also digested as
negative control. (+: clones after digestion; -: clones before digestion)
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Figure 7 Expression of the recombinant TM fusion protein detected by Coomassie blue
staining and Western blot.
The ten candidate recombinant clones identified by both PCR and digestion reaction
were induced in the E. coli strain BL21 on a small scale by IPTG to express His-tag-TM
His
fusion protein. The Coomassie blue staining (A) and Western blot (B) analysis
demonstrated
ated that seven of the ten clones were able to generate 25 kDa His
His--tag-TM
fusion protein.
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Figure 8 Nucleotide and amino acid sequence of HERV-K TM domain induced from
clone #23 comparing the sequence of the TM fusion protein with that of HERV-K37
(GeneBank accession number: DQ112095). Three base pair differences are enclosed in
boxes.
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Figure 9 Purified
urified TM fusion protein detected by Coomassie blue staining and Western
blot.
pQE30-TM
TM clone #23 was selected to express the
The E. coli strain BL21 containing the pQE30
TM fusion protein. The bacteria were induced by 1 mM IPTG overnight at 18°C and the
His-tag-TM
TM fusion protein was purified with affinity chromatography on a Ni2+-NTA
resin column. Coomassie blue staining (left panel) and Western blot (right panel) results
demonstrated the purity of the TM fusion protein with the predicted size.
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3.2 Humoral and cellular immune responses against TM protein in mice
We then asked if HERV-K TM envelope protein could be immunogenic in mice. To
investigate whether the TM fusion protein could induce a humoral TM-targeted immune
response in mice, we performed ELISA to analyze the antibody production by mice
immunized with the recombinant TM fusion protein. The HERV-K TM fusion protein
was produced in E. coli and purified. The HLA-A2 transgenic mice were immunized
subcutaneously followed by three boosts at 1-week intervals. Mice mock-injected with
PBS were used as a control. Sera were collected 10 days after the last boost and a serial
dilution was prepared for testing the anti-TM antibodies by ELISA using TM fusion
protein as the antigen. As illustrated in Figure 10, the HERV-K TM fusion protein was
able to induce much higher TM-specific IgG titers (p<0.0001) in all of the immunized
mice (n=3) than in the mock-immunized mice (n=3).
We next determined the HERV-K TM-specific T cell immune responses induced in
mice assessed by anti-mouse IFN-γ ELISPOT assay. Spleen cells were isolated from the
immunized mice and directly re-stimulated in vitro with TM fusion protein for 18-24 hrs
in ELISPOT plates. Spleen cells from the mock mice were used as a control. As shown
in Figure 11, significantly (p<0.5) higher numbers of IFN-γ secreting cells were
observed in the mice immunized with TM protein than in the mock mice. The number of
IFN-γ secreting cells was calculated by subtracting the average number of spots in wells
of spleen cells re-stimulated in vitro by KLH protein from that of spots in wells of spleen
cells stimulated by KTM.
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Figure 10 ELISA analysis of humoral immune response in mice immunized with
HERV-K TM fusion protein.
Mice were immunized four times with 100 µg purified HERV-K TM protein per mouse
in the presence of adjuvant. Ten days after the last boost, the mice were sacrificed and
sera were collected. To test the anti-TM antibody in the serum, sera were diluted and
analyzed by ELISA using the TM protein of HERV-K as antigen. This figure shows that
anti-HERV-K TM antibody titer is significantly higher in mice immunized with TM
protein than in mock-immunized mice.
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Figure 11 Anti-mouse IFN-γ ELISPOT analysis of the cellular immune response in
mice immunized with HERV-K TM fusion protein.
Spleen cells were isolated from mice immunized with HERV-K TM protein or were
mock-immunized (PBS) and then re-stimulated with TM protein (20 µg/mL) in
ELISPOT plates (5×105 cells per well) for 18-24 hrs prior to spot development and
counting. Data are presented as IFN-γ secreting spleen cells per half million spleen cells
in TM-stimulated samples minus that measured in KLH samples. Significantly more
IFN-γ secreting spleen cells were detected in the immunized mice than in the mock
mice.
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3.3 Expression of HERV-K TM envelope mRNA and protein in human breast
cancer cells
To investigate the expression of HERV-K TM transcripts in human breast cancer cell
lines, RT-PCR analysis was performed using HERV-K TM outer primer pair, which
allowed the amplification of a 591bp DNA product. As shown in Figure 12, the
expression of HERV-K TM mRNA was detected in all five tested human breast cancer
cell lines (i.e., SKBR3, MDA-MB-453, MDA-MB-231, T47D, and MCF7) cultured in
our laboratory, but not the normal breast epithelial cell line MCF10A, which showed a
weak expression of TM mRNA.
We next determined whether HERV-K TM envelope protein was expressed in
human breast cancer cell lines. To do so, we used a polyclonal antibody specific for the
TM envelope protein of HERV-K and analyzed the cellular distribution of viral
components by IFS staining assay. The HERV-K TM-specific antiserum was generated
by immunization of mice with the purified TM protein produced by the recombinant
clone pQE30-TM #23. Both MDA-MB-231 and SKBR3 cells were shown to express the
HERV-K TM protein at approximately the same level (Figure 13 d and f), whereas
cultured MCF10A cells were negative (Figure 13 b). These data are in agreement with
the differences in expression of HERV-K TM-specific mRNA in all three cell lines by
the RT-PCR method. None of the corresponding mock sera was reactive with any of the
cells tested (Figure 13 a, c, and e). As can be clearly observed in Figure 13 d and f, the
TM protein was broadly distributed in the cytoplasm, as expected for a protein
synthesized in the endoplasmic reticulum.
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To determine whether HERV-K TM protein could be detectable in human breast cancer,
we performed IFS on clinical samples from breast cancer patients with detection using
mouse anti-TM sera. Our results show that expression of HERV-K TM protein was
specific for tumor cells (Figure 14). In contrast, the adjacent, non-involved breast cancer
cells showed no TM protein expression. The epithelial phenotype of primary cell culture
was characterized with anti-vimentin and anti-cytokeratin antibodies by IFS (Figure 15).
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750 bp
500 bp

TM

750 bp
500 bp

β-actin

Figure 12 Expression of HERV-K TM mRNA in human breast cancer cell lines as well
as a normal breast epithelial cell line by RT-PCR assay.
Cells from six human breast cancer cell lines (SKBR3, MDA-MB-453, MDA-MB-231,
T47D, and MCF7) and one normal human breast epithelial cell line (MCF10A) were
collected for total RNA isolation using Tri-reagent. Reverse transcriptase PCR was
performed with the TM outer primer pair under the conditions described in the text. All
of the six human breast cancer cell lines presented much stronger expression of HERVK TM mRNA compared to that of the normal breast cell line. β-actin was amplified to
confirm equivalent loading amounts of each sample.
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MD-MBA-231

SKBR3

Figure 13 Expression of HERV-K TM envelope protein in human breast cancer cell
lines as well as a normal breast epithelial cell line by IFS assay.
An immunofluorescence staining assay was performed approximately 24 hr post
inoculation on the human breast cancer and normal breast cell lines grown on the glass
cover slips. MCF10A, MDA-MB-231, and SKBR3 cells were fixed, permeabilized, and
stained for HERV-K TM envelope protein expression with mouse anti-TM serum (b, d,
and f) and with mock serum (a, c, and e), both at a dilution of 1:100 (whole-cell
staining). The figure shows that HERV-K TM protein was expressed in human breast
cancer cell lines, but absent in normal breast cancer cell line. Mock: serum from mice
immunized with PBS; TM: serum from mice immunized with HERV-K TM protein.
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mock

TM
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DCIS T
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d

IDC T
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e
IDC N

Figure 14 Expression of HERV-K TM envelope protein in human breast cancer patient
samples by IFS assay.
An immunofluorescence staining assay was performed with HERV-K anti-TM
antibodies on primary cells cultured from breast cancer patients. The figure shows the
presence of HERV-K TM protein in breast cancer samples (b and d) but its absence from
non-involved adjacent breast tissue samples (f). T: breast tumor tissue; N: uninvolved
breast tissue; DCIS: ductal carcinoma in situ; IDC: invasive ductal carcinoma; mock:
serum from mice immunized with PBS; TM: serum from mice immunized with HERVK TM protein
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IDC N

IDC T
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d
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f

Neg.

Vimentin

Pan-cytokeratin

Figure 15 Characterization of epithelial cells and stromal cells of human breast cancer
patient sample by IFS assay.
A representative IFS assay was performed with anti-vimentin and anti-pan-cytokeratin
antibodies on primary cells cultured from one breast cancer patient. The figure shows the
presence of epithelial cells from breast cancer sample (d and f) and non-involved
adjacent breast tissue samples (c and e). T: breast tumor tissue; N: uninvolved breast
tissue; IDC: invasive ductal carcinoma; neg.: no primary antibody used

47

3.4 Humoral and cellular immune responses against HERV-K TM envelope domain
in breast cancer patients
We next determined the HERV-K TM-specific immune response induced in patients
with breast cancer. First, we tested the antibodies against TM domain in sera from
patient with breast cancer. To evaluate the correlation between the specific humoral
immune response and severity of the disease, ELISA was performed with sera from
breast cancer patients at different stages. Overall, the titer of TM-specific IgG antibodies
was elevated in sera from patients compared to healthy donors. 46% of breast cancer
patients (23 in 50) were positive for antibodies against HERV-K TM envelope protein
(OD>0.5). It was to be noted that all of the tested patients with stage III breast cancer
were positive for TM-specific antibodies (Figure 16). Whereas only around 11.1% of
healthy donors (2 in 18) were positive for TM and the mean absorbance was below 0.5.
Moreover, Figure 16 revealed an increased tendency for anti-TM IgG antibody titers in
patients with breast cancer at higher stage, even though no significant difference was
observed except between patients in groups with cancer in situ and stage III breast
cancer. Similar results were documented for the IgG responses against HERV-K SU
domain produced in the same cohort of breast cancer patients (Figure 17).
Second, we analyzed the T cell responses against HERV-K TM domain induced in
breast cancer patients. To do so, PBMCs were isolated from the blood of breast cancer
patients (see Table 2 for clinic information of patients) and corresponding healthy
female donors. After in vitro stimulation of PBMCs by co-culturing with autologous
DCs pulsed with HERV-K TM fusion protein for 1 week in the presence of rhIL-2, antihuman IFN-γ ELISPOT assay was performed as described in Materials and Methods. A
representative ELISPOT experiment done with two breast cancer patients and two
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healthy donors was shown in Figure 18. For the two breast cancer patient samples, a
significantly increased number of spots was observed in the wells with IVS/TM cells restimulated with autologous DCs pulsed with HERV-K TM protein compared to those
co-cultured with the DCs pulsed with control KLH protein. In contrast, in the two
healthy donors, obviously higher number of IFN-γ secreting cells was not observed in
the IVS/TM cells co-cultured with TM-pulsed DCs than in the IVS/TM cells with KLHpulsed DCs. Furthermore, a much higher IFN-γ response was induced after IVS using
autologous TM-pulsed DCs in the two patient samples than in the two normal donors.
The similar increased IFNγ production was evident in the IVS/SU cells re-stimulated by
protein-pulsed DCs in the two cancer patients compared to the two healthy individuals.
The IFNγ ELISPOT data with 21 breast cancer patients and 12 healthy normal donors
was summarized in Figure 19. Compared to the healthy donors, the results from the
breast cancer patient samples showed that a significantly enhanced number of IFN-γ
secreting cells was observed in IVS TM cells (Figure 19A) as well as IVS SU cells
(figure 19B) after re-stimulation with autologous DCs pulsed with corresponding protein
in the ELISPOT plates.
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Figure 16 ELISA for anti-HERV-K TM antibody levels in serum from human breast
cancer patients. ELISA assays to detect anti-HERV-K TM antibody levels were carried
out in serum at a dilution of 1:100 from patients with breast cancer at different stages or
from healthy donors. Purified HERV-K TM fusion protein was used as the antigen.
Horizontal bars are shown as the mean and each point represents an average of three
measurements for each sample. This figure shows that the tendency for the TM antibody
level to be increased was likely related to the severity of breast cancer. The significant
difference among the groups was analysed by ANOVA test.
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Figure 17 ELISA for anti-HERV-K SU antibody levels in serum from human breast
cancer patients. ELISA assays to detect anti-HERV-K SU antibody level were carried
out in serum at a dilution of 1:100 from patients with breast cancer at different stages or
from healthy donors. Purified HERV-K SU fusion protein was used as the antigen.
Horizontal bars are shown as the mean and each point represents an average of three
measurements for each sample. This figure shows that the tendency for the SU antibody
level to be increased was likely related to the severity of breast cancer. The significant
difference among the groups was analysed by ANOVA test.
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Table 2 Summary of clinical information for the 21 patients with breast cancer.
Patie
nt
samp
le

Age/Race/S
ex

BC01
BC02
BC03
BC04
BC05
BC06
BC07
BC08
BC09
BC10
BC11
BC12
BC13
BC14
BC15
BC16
BC17
BC18
BC19
BC20
BC21
BC22

44/w/f
46/h/f
67/w/f
83/w/f
60/w/f
50/b/f
64/w/f
44/w/f
55/w/f
63/w/f
67/w/f
59/w/f
50/w/f
46/w/f
68/w/f
52/w/f
60/w/f
41/w/f
58/w/f
39/h/f
55/w/f
64/w/f

Diagnos ER PR
is

ILC
ILC
IDC
IDC
IDC
IDC
IDC
IDC
IDC
IDC
IDC
DCIS
DCIS
DCIS
DCIS
DCIS
DCIS
DCIS
DCIS
DCIS
DCIS
DCIS+I
DC

+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+

+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+

Her2/neu

LN
status

Nuclear
grade

Tumor
Size
(cm)

+
+
n/a
n/a
n/a
n/a
+
+

None
Left
None
None
None
None
None
None
Right
None
None
None
None
None
None
None
None
None
None
None
None
None

1
2
1
1
2
2
3
3
3
3
3
2
2
2
2
2
3
3
3
3
3
3

7.2
1.5
5.0
1.5
2.5
1.0
1.7
3.4
6.0
4.3
2.0
n/a
1.4
2.7
0.10
2.3
2.9
2.0
n/a
1.9
8.0
n/a

Abbreviations: ILC, invasive lobular carcinoma; IDC, invasive ductal carcinoma; DCIS,
ductal carcinoma in situ; LN, lymph node; PR, progesterone receptor; ER, estrogen
receptor; n/a, not available
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DCIS

IDC

ND1

ND2

Figure 18 A representative ELISPOT assay for testing HERV-K SU/TM specific T-cell
responses in human breast cancer patients and healthy donors.
PBMCs, IVS SU, and IVS TM cells (5×104 cells per well) from two patients with breast
cancer and two healthy donors were co-cultured with autologous protein-pulsed DCs for
18-24 hrs as detailed in Materials and Methods. All samples were tested in triplicate.
This figure shows that many more spots were detected in both IVS SU and IVS TM cells
from two patients than from the two healthy donors. ND: normal donor; DCIS: ductal
carcinoma in situ; IDC: invasive ductal carcinoma
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A

B

Figure 19 Quantitative assessment of HERV-K SU/TM specific T-cell responses in
human breast cancer patients and healthy donors by anti-human IFN-γ ELISPOT assay.
These two graphs summarize the ESLIPOT data testing the HERV-K SU/TM specific Tcell responses in 21 patients with breast cancer as well as 12 healthy donors. Each circle
represents the average amount of IFN-γ-secreting cells of three measurements for each
sample and the horizontal bars show the mean value. The data suggest that specific Tcell responses against both TM (A) and SU (B) protein were induced in breast cancer
patients. The black circles refer to the IFN-γ secreting IVS cells co-cultured with KLHpulsed DCs and the white circles refer to those co-cultured DCs pulsed with HERV-K
TM (A) or SU (B) protein. ND, normal donors; BC, breast cancer
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Chapter 4 Discussion
In humans, the majority of the endogenous retroviruses are defective and not
expressed although they make up about 8% of the human genome. Only HERV-K,
however, has maintained intact ORFs for gag, pro, pol and env. The expression of
mRNA and proteins of HERV-K and even the production of retroviral particles have
been detected in some types of human cancers including breast cancer (30, 34, 37).
Although enhanced levels of HERV-K SU env expression have been found in human
breast cancer (30, 38), little is known about the expression of endogenous retroviral TM
Env protein in human cancers (Table 1). Here, we confirmed and extended data on the
expression and the immunological characterization of HERV-K TM envelope domain
and revealed the potential value of TM as a promising tumor target for breast cancer
diagnosis and immunotherapy.
In this work, we have isolated a gene encoding the HERV-K TM envelope domain
from a human melanoma patient and expressed the purified TM protein. The TM gene
sequence possesses extremely high identity (99%) with the sequence of the TM gene of
HERV-K37 (Figure 8) and the purified TM protein possesses exactly the same amino
acid sequence as the HERV-K 37 since all three variant nucleic acids are located in the
third position of the triplet codons. HERV-K 37 was estimated to integrate into the
germline genome approximately 0.5 million years ago and thus is considered an
evolutionary young HERV-K family (39).
Although it was previously shown by our group and others that HERV-K SU env
gene was expressed at both the mRNA and protein levels, to our knowledge, so far there
has been no report showing evidence of TM domain expression in human breast cancer.
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We have shown here that the HERV-K TM mRNA was expressed in all tested human
breast cancer cell lines but not in the normal human breast cell line MCF10A by RTPCR (Figure 12). Moreover, TM protein was exclusively expressed in human breast
cancer cell lines as well as in human breast cancer specimens by IFS analysis (Figure 13,
14). These results supported the assumption that the HERV K TM env domain is specific
to human breast cancer.
The detection of retroviral protein expression in breast cancer patients further raises
the question about the association between the expression of retroviruses and the
transformation and progression of human breast cancer. It is estimated that the reactivation of retroviral proteins in human cancers would be the consequence of increased
transcriptional and translational activation during tumor development and progression.
As a transposable element, HERV-K may also be actively involved in malignant
transformation by insertional mutagenesis. In addition, there is recent evidence that two
accessory proteins encoded by HERV-K, Rec and NP9, are potential oncogenes
contributing to cellular transformation and induction of tumor formation in mice (40).
Another possible reason for retroviral protein overexpression in cancers concerns
their correlation with the immunosuppressive activity of the retroviruses. Many
retroviruses have been found to be capable of inducing immunosuppression to protect
from immunologic rejection consequent of transformed cells (41). The expression of the
envelope protein of retroviruses, including infectious retroviruses such as Moloney
murine leukemia virus (MoMLV) and HTLV as well as endogenous retroviruses like
HERV-H, enables the transformed cells to grow in allogeneic immunocompetent mice
(22, 41, 42). It has been verified that the immunosuppressive activity is mediated by the

56

conserved transmembrane envelope protein of retroviruses, for example, p15E of
MoMLV and feline leukemia virus (FLV) and gp21 of HTLV-1 and HTLV-2, which can
inhibit lymphocyte proliferation and cytolytic activity of human natural killer cells, and
modulate cytokine production (22, 43). A seventeen amino acid peptide CKS-17
(LQNRRGLDLLFLKEGGL), a synthetic peptide corresponding to a highly conserved
domain (i.e., ISD) of the TM protein, has been found to be the exact domain presenting
the immunosuppression activity (44). Some reports have verified that the retroviral ISD
can induce very low IgG titers in mice, whereas the mutant non-IS form induces much
higher humoral response (41, 45).
However, in this present study, we discovered that the HERV-K TM envelope
protein is capable of triggering strong humoral immune responses. The ELISA results
with mice showed that the TM protein induced significantly high titers of TM-specific
antibodies in sera from all TM-immunized mice (Figure 10). The HERV-K TM envelope
protein was further characterized in patients with breast cancer. Our results show that
around 50% of the patients (n=50) with breast cancer produced antibodies directed
against the TM protein of HERV-K (Figure 16). Such antibodies were detectable at a
lower frequency in the healthy donors (11.1%, n=18) with lower mean absorbance value.
However, it should be noted that a few healthy individuals had unexpected anti-HERVK TM antibody, suggesting that events other than breast cancer may lead to the aberrant
HERV-K TM expression and anti-TM immunity. Furthermore, research by another
group suggests that antibodies directed against HERV-K TM envelope protein are also
present in melanoma patients (34, 46). Such antibodies were detected at a very low
frequency in normal blood donors. This discrepancy may be explained by phylogenetic
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analysis based on the TM proteins. Although the TM domain is conserved and the ISD
can be found in the majority of the known retroviruses, there are a few exceptions which
do not possess the motif (including MMTV and HERV-K) (3).
It was documented that the detection of antibodies against HERV-K proteins was of
diagnostic and prognostic value in patients with germ cell cancer and melanoma (34,
47). Consistently, our ELISA study performed here reveals a positive correlation
between anti-HERV-K TM serum reactivity and tumor progression. Considering the
limited population tested, however, further prospective studies are needed to confirm this
result with a larger sample size.
Having identified the humoral immune response against HERV-K TM protein, it was
important to determine the TM-specific T cell response. ELISPOT assay is a common
used method to monitor T cell immune response in humans and animals. Here, we
performed IFN-γ ELISPOT assay to determine the cellular immune response in
immunized mice and breast cancer patients. Anti-mouse IFN-γ ELISPOT results show
that a putative specific T cell response against HERV-K TM protein was identified in
TM-immunized mice (Figure 11). Moreover, anti-human IFN-γ ELISPOT assay was
performed using PBMCs from breast cancer patients after a single in vitro stimulation;
results showed that HERV-K TM protein could induce significantly higher T cell
response in breast cancer patients than in healthy donors (Figure 18, 19).
Although the exact role of HERV-K TM envelope protein in tumorigenesis remains
unclear, the exclusive overexpression in breast cancer cells and the specific immune
responses induced in patients with breast cancer make it a potentially valuable source of
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tumor antigens for cancer vaccination and immunotherapy. Anti-HERV-K TM env
antibodies may also be used as a screening tool for breast cancer.
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Chapter 5 Conclusion and Future Studies
5.1 Conclusion
We constructed a prokaryotic expression plasmid containing the gene encoding
HERV-K TM envelope domain (pQE30-TM) and generated purified 6-His tagged TM
fusion protein. We found TM mRNA and protein were exclusively expressed in human
breast cancer cells. The HERV-K SU immunity profile confirmed our previous findings
(30); however, our research challenged the prevailing data regarding the immunity of
retroviral TM protein in breast cancer. Our results suggest that HERV-K TM protein can
induce both humoral and cellular immune responses in human breast cancer patients and
immunized mice. Moreover, the data in our study clearly document a strong association
between HERV-K TM antibodies and the clinical manifestations of breast cancer
patients. Our findings expand the current knowledge of HERV-K in breast cancer and
suggest HERV-K TM may represent a novel source of breast cancer antigen for cancer
immunotherapy, prevention, diagnosis, and prognosis.
5.2 Future studies
Future research is required to validate our findings in a larger cohort of breast cancer
patients and corresponding healthy donors. In addition, more assays, such as CTL assay
and T cell proliferation assay, will be needed to confirm the immunogenic characteristics
of HERV-K TM protein in breast cancer. Furthermore, determination of potent
immunogenic peptides within the TM domain would provide the basis for generation of
anti-tumor vaccines.
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